A lawmaker is calling for the U.S. to cut reliance on imported pharmaceuticals and revive domestic drug production to mitigate risks highlighted by recent cases of contaminated medications. The push follows concerns that foreign supply chains may leave the country vulnerable to disruptions or safety threats. Advocates argue that strengthening domestic manufacturing could improve both security and oversight of critical medical supplies. The debate comes as lawmakers weigh how to balance cost, access, and resilience in the pharmaceutical industry.
Rep. Bob Onder argues that the United States must reduce its dependence on foreign pharmaceutical supplies and rebuild domestic manufacturing capacity to address national security vulnerabilities exposed by recent drug contaminations.
